Company Overview

AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company focused on developing precision medicines for neurodegenerative diseases associated with protein misfolding, including Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative disorders. The company operates within the biotechnology and central nervous system (CNS) therapeutics industries, with its core activities centered on research, development, and commercialization partnerships involving disease-modifying therapies and diagnostic technologies. According to publicly available disclosures including SEC filings and company investor materials, AC Immune’s primary revenue sources have historically consisted of collaboration agreements, licensing arrangements, milestone payments, and research funding tied to strategic pharmaceutical partnerships rather than commercial product sales.

The company’s technology platforms are designed to target toxic forms of proteins such as beta-amyloid, tau, and alpha-synuclein. AC Immune has developed multiple proprietary platforms, including antibody-based therapeutics, small molecules, and diagnostic imaging agents. Its strategic positioning is based on early-stage biomarker integration and precision medicine approaches intended to identify pathological protein conformations before extensive neurodegeneration occurs. Founded in 2003 and headquartered in Lausanne, Switzerland, AC Immune evolved from an academic-science-driven biotechnology company into a publicly traded clinical-stage enterprise listed on Nasdaq under the ticker ACIU.

Business Operations

AC Immune organizes its operations around proprietary technology platforms and partnered clinical development programs targeting neurodegenerative disease mechanisms. Key operational areas include the company’s SupraAntigen®, Morphomer®, and diagnostic imaging platforms, which support development of monoclonal antibodies, vaccines, small molecules, and positron emission tomography (PET) tracers. The company generates revenue primarily through collaboration agreements with larger pharmaceutical organizations, including upfront licensing payments, milestone achievements, and research support tied to ongoing development activities. Public disclosures indicate that AC Immune does not currently derive material recurring revenue from approved commercial therapeutics.

The company maintains both domestic Swiss operations and international collaborations, particularly in North America and Europe. AC Immune has established strategic partnerships with companies including Johnson & Johnson, Genentech, Takeda, and Life Molecular Imaging for selected therapeutic and diagnostic programs. Its operational assets include proprietary intellectual property portfolios, clinical-stage biologics programs, neurodegenerative disease biomarker technologies, and translational neuroscience research capabilities. Several development programs have advanced into human clinical trials, including therapies targeting tau and alpha-synuclein pathologies.

Strategic Position & Investments

AC Immune’s strategic direction emphasizes disease-modifying therapies for neurodegenerative diseases using precision diagnostics and biomarker-guided patient selection. The company has focused heavily on advancing anti-tau and anti-alpha-synuclein therapeutics, areas viewed within the biotechnology sector as important next-generation targets beyond traditional amyloid-focused Alzheimer’s therapies. Company filings and investor presentations indicate that AC Immune seeks to reduce development risk through co-development structures and strategic licensing agreements with larger pharmaceutical companies capable of supporting late-stage clinical trials and commercialization.

Major strategic collaborations include partnerships involving anti-tau antibodies and alpha-synuclein programs with Johnson & Johnson and historical collaborations involving Genentech and Takeda. AC Immune has also invested in diagnostic imaging technologies through arrangements with Life Molecular Imaging, particularly for tau PET tracers intended to support early disease detection and therapeutic monitoring. The company remains active in emerging neurodegenerative therapeutic areas including precision neurology, biomarker-based diagnostics, immunotherapy, and protein aggregation inhibition. Available public information does not indicate a broad portfolio of majority-owned operating subsidiaries comparable to diversified pharmaceutical holding structures.

Geographic Footprint

AC Immune is headquartered in Lausanne, Switzerland, and conducts research and development activities primarily from Switzerland while maintaining strategic relationships across North America, Europe, and parts of Asia through pharmaceutical collaborations and clinical trial networks. The company’s Nasdaq listing provides access to U.S. capital markets, and many of its major development partnerships involve multinational pharmaceutical companies with global commercialization capabilities.

The company’s clinical programs have involved trial activity in multiple international jurisdictions, reflecting the global nature of neurodegenerative disease research and regulatory development. AC Immune’s operational influence is concentrated in developed pharmaceutical markets, particularly the United States and Europe, where collaboration partners support clinical advancement, regulatory engagement, and potential future commercialization efforts. Public disclosures confirm that AC Immune’s business model relies significantly on international scientific collaboration rather than large-scale standalone commercial infrastructure.

Leadership & Governance

AC Immune was founded by neuroscientist Andrea Pfeifer, who has played a central role in shaping the company’s scientific and strategic direction. The company’s leadership philosophy has emphasized translational neuroscience, early biomarker integration, and precision medicine approaches aimed at identifying and treating neurodegenerative diseases before irreversible neuronal damage occurs. Corporate governance and strategic priorities are disclosed through annual reports, investor communications, and SEC filings, which emphasize partnership-driven development and disciplined capital allocation.

Key executives and leadership figures include:

• Andrea Pfeifer – Chief Executive Officer
• Katja Wildi – Chief Financial Officer
• Samuel Dyer – Chief Business Officer
• Frédéric Calcagno – Senior Vice President and Head of Technical Operations
• Enrico Noseda – Chief Scientific Officer

Publicly available information indicates that AC Immune’s board and executive leadership possess backgrounds spanning biotechnology research, pharmaceutical development, neurology, and global healthcare finance. Leadership strategy has consistently focused on advancing differentiated neurodegenerative disease therapies through collaborative development models and proprietary protein-misfolding technologies.